Actively Recruiting
Investigate New Pneumococcal Conjugate Vaccines PCV20 and PCV21 for Cross-protection Against Serogroup 33 Pneumococcal Disease
Led by University of Alabama at Birmingham · Updated on 2026-05-05
70
Participants Needed
1
Research Sites
21 weeks
Total Duration
On this page
Sponsors
U
University of Alabama at Birmingham
Lead Sponsor
M
Merck Sharp & Dohme LLC
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating two different pneumococcal conjugate vaccines to understand how well they produce antibodies that defend against certain types of bacteria, specifically focusing on serogroup 33. The study aims to compare the effectiveness of these vaccines in creating antibodies that can kill bacteria, helping to prevent pneumococcal disease. Participants will be randomly assigned to receive one of two vaccines: PCV20 or PCV21. Both are biological pneumococcal vaccines given to healthy adults, and the study is conducted without masking or blinding. This is a Phase 4 interventional trial sponsored by the University of Alabama at Birmingham. During the study, researchers will measure antibody levels and the ability of these antibodies to kill bacteria four weeks after vaccination. Healthy adults aged 18 and older will be involved, and the trial includes follow-up to evaluate immune response. Participants should not have previously received pneumococcal vaccination or be taking immunosuppressing medications. The study is expected to continue until August 2027.
CONDITIONS
Brief Title
Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy adult aged 18 years or older
You will not qualify if you...
- No prior history of pneumococcal vaccination
- No use of immunosuppressing medications or presence of chronic diseases that affect immune function
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single day
Participants receive one dose of the pneumococcal conjugate vaccine (PCV20 or PCV21).
1 vaccination visit (in-person)
Duration - 4 weeks
Participants are monitored for antibody response and antibody-mediated killing 4 weeks after vaccination.
1 follow-up visit (in-person)
Trial Site Locations
Total: 1 location
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
Actively Recruiting
Research Team
D
David LaFon, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here